Views & Analysis

Views & Analysis
Almirall looks for action in eczema

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.

Views & Analysis
Professor Nigel Osbourne on medical music

Medical music to calm the nerves

Dominic Tyer looks at the clinical studies evaluating music as an unconventional but promising treatment for some patients.

R&D
Patients in the driving seat

Patients in the driving seat

Many pharma companies talk about the importance of ‘patient centric’ clinical trials and involving patients in trial design – but what does this really mean?

Views & Analysis
Who will pay the price for inaction on superbugs

Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been